In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 381 to 390 of 441

TitleTypeExpected publication date
Suspected cancer updateQuality standardTBC
Suspected Cancer: recognition and referral (update)NICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidance
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Technology appraisal guidance
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All